Company’s operations were a single reportable segment and an international segment. The differences between the U.S. federal statutory tax rate and the Company’s effective tax rateinternational segment operations are as follows:

immaterial. See Note 2 – Summary of Significant Accounting Policies (Continued)7. 

Recent Accounting Pronouncements

The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Those ASUs issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.

On February 25, 2016, the FASB issued Topic 842, its highly-anticipated leasing standard for both lessees and lessors. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. The amendments are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. At inception, a lessee must classify all leases as either finance or operating. The Company intends to adopt Topic 842 upon extension of the current lease for its facilities in Elk Grove Village or upon entering into a new lease agreement for alternative facilities on or about May 1, 2018. The Company is investigating the effect of adoption of Topic 842 on its results of operations and financial condition. However, it is not anticipated that adoption of Topic 842 will have a material impact on the results of operations or financial condition of the Company.

In May 2014, the Financial Accounting Standard Board (FASB) issued ASU 2014-09, Revenue from Contract with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 and subsequent amendments supersede the revenue recognition requirements in ASC Topic 605, Revenue Recognition, and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and have not yet determined the method by which we will adopt the standards as of May 1, 2018.

Note 3 – Inventories

Components of inventories are as follows:

Note 4 – Common Stock

The Company’s common stock is traded in the over-the-counter market. However, there is no established public trading market due to limited and sporadic trades. The Company’s common stock is not listed on a recognized market or stock exchange.

Note 5 - Related Party Transactions

The Company and its affiliates are related through common stock ownership as follows as of JanuaryJuly 31, 2018:2019:

Stock of Affiliates

As of JanuaryJuly 31, 2018,2019, $19,699 was due from F. K. Suzuki International, Inc. (“FKSI”). These balances result from an allocation of common expenses charged to FKSI prior to April 30, 2006 offset by advances received from time to time. No interest income is received or accrued by the Company. The financial condition of FKSI is such that it will unlikely be able to repay the Company during the next year without liquidating a portion of its assets, including a portion of its ownership in the Company. As a result, the receivable balance has been reclassified as a contra equity account since April 30, 2006.

A board member provided a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $21,988$4,624 and $15,848$8,706 for the ninethree months ended JanuaryJuly 31, 20182019 and 2017,2018 respectively.

Note 6 – Lease Commitments

On February 25, 2016, the FASB issued Topic 842, Leases. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. At inception, a lessee must classify all leases as either finance or operating. In January 2015,February 2018, the Company entered into a three-yeartwo-year lease agreement for its current facilities, which started May 1, 2018 and expires on April 30, 2018. The base rent under2020. Under the new lease escalates overstandard, which was early adopted by the lifeCompany as of the lease. However, rent expense is recorded on a straight-line basis as required by accounting principles generally accepted in the United States of America. As of January 31,May 1, 2018, the Company’s approximate total future minimum lease payments arewas accounted for as follows:

Also included inan operating lease. As a result, the Company measured the lease liability using the two year term and rates per the lease agreement are escalation clausesand recognized a lease liability, with a corresponding right-of-use asset. A discount was not calculated due to the lease agreement only having a two year term.

The operating lease expense for the lessor’s increasesthree months ending July 31, 2019 was $22,275. Retrospective application of the new standard did not render any adjustments since all of the Company’s operating leases were less than one year.

Maturities of lease liabilities as of July 31, 2019 are presented in property taxes and other operating expenses. The Company is currentlyin negotiations to extend the lease agreement.following table:

Year Ending April 30 2020: $66,825

Note 7 – Customer Concentrations

Shipments to one customer amounted to 28.24%28.28% of sales during the first ninethree months of Fiscal 20182020 compared to 27.1%31.87% during the comparative Fiscal 20172019 period. As of JanuaryJuly 31, 2018,2019, there were outstanding accounts receivable from this customer of $54,732$68,161 compared to $67,535$66,518 at JanuaryJuly 31, 2017.2018. Shipments to another customer amounted to 36.67%36.96% of sales during the first ninethree months of Fiscal 20182020 and 36.7%36.42% of sales during the first ninethree months of Fiscal 2017.2019. As of JanuaryJuly 31, 2018,2019, there were outstanding accounts receivable from this customer of $136,466$128,026 compared to $152,440$123,166 at JanuaryJuly 31, 2017.2018.

The Company had export sales of $32,120$7,310 during the first ninethree months of Fiscal 2018,2020, and export sales of $7,160 during the Quarter ending January 31, 2018. The Company had export sales of $46,595$10,790 during the first ninethree months of Fiscal 2017, and export sales of $16,505 during the Quarter ending January 31, 2017.2019. The Company also believes that some of its medical devices were sold to distributors within the United States who resold the devices in foreign markets. However, the Company does not have any information regarding such sales and such sales are not considered to be material.

Item 2.Management’s Discussion of Financial Condition and Results of OperationsMANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Net Sales/Revenues

For the three month period ending JanuaryJuly 31, 20182019 (“31^rdst Quarter”), the net sales decreased 9.54%.33%, or $32,667, and decreased 5.05%, or $49,641, during the nine month period ending January 31, 2018,$1,047, as compared to net sales for the comparative periodsthree month period ending in 2017.2018. The decrease in net sales during the three1^st Quarter was primarily due to a decrease of $3,305 in LabTemp^® and nine month periods ending January 31, 2018 is primarily the result of lower HemoTemp^R® II and TempTrend sales. At JanuaryActivator sales offset by an increase in HemoTemp^® II sales of $2,655. As of July 31, 2018 there were2019, the Company had no back orders.

In addition to the above, during the 31^rdst Quarter the Company had $569$480 of other miscellaneous revenues primarily from interest income and leasing a portion of its storage space to an unrelated party.a third party and interest income of $150.

Costs and Expenses

General

The operating expenses of the Company during the 31^rdst Quarter increaseddecreased overall by 4.07%.87%, or $7,328,$1,730, as compared to the 3^rd quarter in 2017three month period ending July 31, 2018, primarily due to an increasea decrease in employee wages, FDA user feesgeneral and legal fees. The operating expenses of the Company increased by 5.04% or $28,580 for the nine month period ending January 31, 2018, as compared to the nine month period ending January 31, 2017 primarily due to an increase in legal fees, general insurance and chemical waste disposal fees.administrative expenses.

Cost of Sales

The cost of sales during the 31^rdst Quarter increased by $25,963, and also increased by $25,997 during the nine month period ending January 31, 2018$3,261 as compared to these expenses during the same periodsthree month period ending in 2017. TheJuly 31, 2018. This increase in the cost of sales during the 3^rd Quarter was due primarily due to the addition of a full-timehigher salaries and related employee and an increase in the cost of health insurance and certain raw materials.expenses. As a percentage of sales, the cost of sales were 37.42%was 33.83% during the 31^rdst Quarter 26.26%and 32.69% for the comparative quarter ending in 2017, and 32.48% during the ninethree month period ending JanuaryJuly 31, 2018 compared to 28.19% in 2017.2018. Subject to unanticipated changesincreases in the price of raw materials or extraordinary occurrences, it is not anticipated that the cost of sales as a percentage of sales will materially change in the near future.

Research and Development Expenses

Research and Development costs increased $1,182, or 2.82%, duringfor the 31^rdst Quarter increased by $3,001, or 8.13%, as compared to the same quarter in 2017. These costs increased by $11,856, or 9.74%, during the nine month period ending January 31, 2018 as compared to the same period in 2017.fiscal 2018. The overall cost in research and development expense increased during the nine monthsincrease was mainly due to chemical waste disposal fees, consulting feeshigher salaries and higher FDA user fees.related employee expenses and books for research. The Company is continuing its investigation and development of certain productsresearch intended to improve and expand itsthe Company’s current product line. The Company does not have sufficient information to determine the extent to which its resourcesthe Company will be required to completeallocate its resources to the continued development of suchthese products.

Marketing Expenses

Marketing expenses for the 3rd1^st Quarter increased by $1,999, or 4.36%,$2,093 as compared to the quarter ending JanuaryJuly 31, 2017. These costs increased by $1,955, or 1.40%, during the nine month period ending January 31, 2018 as compared to the same period in 2017.2018. The increase is primarilywas due to marketing travel and higher employee costs.

expenses.

General and Administrative Expenses

General and administrative costs for the 31^rdst Quarter increaseddecreased by $4,147,$6,824, or 4.49%5.82%, as compared to the 3^rd quarter ending January 31, 2017, primarily due to higher legal fees and employee expenses. General and administrative costs have increased overall by $14,769, or 4.83%, during the nine month period ending JanuaryJuly 31, 2018, as compared to2018. This decrease was primarily the same periodsresult of a decrease in 2018, primarily due to higher legal fees,fees. Except for unforeseen expenses and normal increases in employee costs, it is unlikely general insurance and employee expenses.administrative expenses will materially change during Fiscal 2020.

Net Income

The Company realized a net income of $5,097$8,578 during the 31^rdst Quarter as compared to a net income of $49,606$10,379 for the comparative quarter inof the prior yearyear. The reduction in net income during the first quarter was primarily due to lower sales during the 3^rd quarter. The Company also realized a net income of $28,399 for the nine month period ending January 31, 2018 as compared to a net income of $96,064 during the same period in 2017. This decrease in net income is due to an overall decrease inreduced sales.

Assets/Liabilities

General

Since April 30, 2017,2019, the Company'sCompany’s assets have increaseddecreased by $8,464$22,429 and liabilities have decreased by $19,935.$31,007. The increaseoverall decrease in assets such as cash and prepaid expenses,liabilities is a resultprimarily due to the changes in the accounting treatment for leases, which include amortization of the Company’s continued profitabilityright of use asset and cash generated from operations.payments against the lease liability.

Related Party Transactions

The Company was owed $19,699 by F.K. Suzuki International, Inc. ("FKSI"), an affiliate, at JanuaryJuly 31, 20182019 and April 30, 2017.2019. This account primarily represents common expenses which were previously charged by the Company to FKSI for reimbursement. No interest is received or accrued by the Company. Collectability of the amounts due from FKSI since April 30, 2006 could not be assured without the liquidation of all or a portion of its assets, including a portion of its common stock of the Company. As a result, as of April 30, 2006, all of the amount owed by FKSI to the Company was reclassified as a reduction of FKSI’s capital in the Company.

A board member provides a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $4,624 and $8,706 at July 31, 2019 and 2018, respectively.

Current Assets/Liabilities Ratio

The ratio of current assets to current liabilities, 29.9313.18 to 1, has increased compared to 21.2910.5 to 1 at April 30, 2017. This increase in2019, primarily due to higher cash balances and lower operating lease liability. The Company anticipates the ratio of current assets to current liabilities iswill remain substantially at its current level as a result of increased cash and prepaid expenses and a reductionthe change in accrued expenses.accounting methods, subject to other normal fluctuations. In order to maintain or improve the Company’s asset/liabilities ratio, the Company’s operations must remain profitable.

Liquidity and Capital Resources

During the nine month period ending January 31, 2018,1^st Quarter, the Company experienced an increase in working capital of $42,469.$35,683. This iswas primarily due to the Company’s increase inhigher cash balances and prepaid expenses and a reduction in accrued expenses.lower operating lease liability.

The Company has attempted to conserve working capital whenever possible. To this end, the Company attempts to keep inventory at minimum levels. The Company believes that it will be able to maintain adequate inventory to supply its customers on a timely basis by careful planning and forecasting demand for its products. However, the Company is nevertheless required to carry a minimum amount of finished inventory and raw materials to meet the delivery requirements of customers and thus, inventory represents a materialsubstantial portion of the Company’s investment in current assets.

The Company presently grants payment terms to customers and dealers. Although the Company experiences varying collection periods of its accounts receivable, based on past experience, the Company believes that uncollectableuncollectible accounts receivable will not have a significant effect on future liquidity.

Cash provided by operating activities was $92,110$33,522 during the ninethree month period ending JanuaryJuly 31, 2018. Nothing2019. There was no cash used for equipment purchases or patent application expenditures during this same period.in investing activities. Except for its operating working capital, limited equipment purchases and patent expenses,procurement costs, management is not aware of any other material capital requirements or material contingencies for which it must provide. There were no cash flows from financing activities during the ninethree month periodsperiod ending JanuaryJuly 31, 20182019 or 2017.2018.

As of JanuaryJuly 31, 2018,2019, the Company had $1,549,138$1,651,500 of current assets available. Of this amount, $52,233$50,614 was prepaid expenses, $133,939$158,038 was inventory, $230,274$229,201 was net trade receivables and $1,132,692$1,213,647 was cash. The Company’s available cash and cash flow from operations isare considered adequate to fund the short-term operating capital needs of the Company. The Company does not have a working line of credit, and does not anticipate obtaining a working line of credit in the near future. ThereThus there is a risk additional financing may be necessary to fund long-term capital needs of the Company.Company, although there is no such currently known long-term capital needs other than operations.

Effects of Inflation. With the exception of inventory, and labor costs and product sales prices increasing with inflation, inflation has not had a material effect on the Company’s revenues and income from continuing operations in the past three years. Inflation is not expected to have a material effect on the Company’s revenues or income in the foreseeable future.

Critical Accounting Policies and Estimates. On December 12, 2001, the SEC issued FR-60 “Cautionary Advice Regarding Disclosure About Critical Accounting Policies.” FR-60 is an intermediate step to alert companies to the need for greater investor awareness of the sensitivity of financial statements to the methods, assumptions, and estimates underlying their preparation, including the judgments and uncertainties affecting the application of those policies and the likelihood that materially different amounts would be reported under different conditions or using different assumptions.

The Company’s significant accounting policies are disclosed in Note 2 to the Financial Statements for the 3rd1^st Quarter. See “Financial Statements.” Except as noted below, the impact on the Company’s financial position or results of operation would not have been materially different had the Company reported under different conditions or usedusing different assumptions. The policies which may have materially affected the financial position and results of operations of the Company if such information had been reported under different circumstances or assumptions are:

Use of Estimates - preparation. Preparation of financial statements and conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting period. The financial condition of the Company and results of operations may differ from the estimates and assumptions made by management in preparation of the Financial Statements accompanying this report.

Allowance for Bad Debts -. The Company periodically performs credit evaluations of its customers and generally does not require collateral to support amounts due from the sale of its products. The Company maintains an allowance for doubtful accounts based on its best estimate of the collectability of accounts receivable.

Forward-Looking Statements

This report may contain statements which, to the extent they are not recitations of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Such forward-looking statements involve risks and uncertainties. Actual results may differ materially from such forward-looking statements for reasons including, but not limited to, changes to and developments in the legislative and regulatory environments effecting the Company’s business, the impact of competitive products and services, changes in the medical and laboratory industries caused by various factors, risks inherit in marketing new products, as well as other factors as set forth in this report. Thus, such forward-looking statements should not be relied upon to indicate the actual results which might be obtained by the Company. No representation or warranty of any kind is given with respect to the accuracy of such forward-looking information. The forward-looking information has been prepared by the management of the Company and has not been reviewed or compiled by independent public accountants.

Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates and commodity prices. Historically, theThe Company’s primary exposure to market risk has beenis the interest rate risk associated with its short term money market investments. The Company currently does not have any money market investments. The Company does not have any financial instruments held for trading or other speculative purposes and does not invest in derivative financial instruments, interest rate swaps or other investments that alter interest rate exposure. Thus, theThe Company does not have any credit facilities with variable interest rates. TheThus, the Company’s operations are not exposed to financial risk that will have a material impact on its financial position and results of operation.

Disclosure Controls and Procedures

The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) which are controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Accounting Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company’s Chief Executive Officer and Chief Accounting Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in

Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and its Chief Accounting Officer have concluded that the Company’s disclosure controls and procedures are effective.

There have been no changes in the Company’s internal control over financial reporting during the Company’s Fiscal Quarter ending JanuaryJuly 31, 20182019 that have materially affected or are likely to materially affect the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.Legal Proceedings.

As of the end of the Company’s Fiscal Quarter ending JanuaryJuly 31, 2018,2019, there are no material pending legal proceedings to which the Company or any of its subsidiaries is a party to of which any of their property is the subject.

Item 1A.Risk Factors.

In addition to the other information set forth in this report on Form 10-Q, you should also consider the factors, risks and uncertainties which could materially affect the Company’s business, financial condition or future results as discussed in Part I, Item 1A – “Risk Factors” of our Annual Report on Form 10-K10-K/A for the fiscal year ended April 30, 2017.2019. There were no significant changes to the risk factors identified on the Form 10-K10-K/A for the fiscal year ended April 30, 20172019 or during the thirdfirst quarter of Fiscal 2018.2020.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.

During the past three years, the Company has not sold securities which were not registered under the Securities Act.

Item 3.Defaults Upon Senior Securities.

Item 4.Mine Safety Disclosures.

The disclosures required by this Item are not applicable to the Company.

The disclosures required by this Item are not applicable to the Company.

(a)       The Company is not required to disclose any information in this Form 10-Q otherwise required to be disclosed in a report on Form 8-K during the period covered by this Form 10-Q.

(b)       During the Fiscal Quarter ending January 31, 2018, there have been no material changes to the procedures by which the security holders may recommend nominees to the Company’s board of directors, where such changes were implemented after the Company last provided disclosure in response to the requirements of Regulation S-K.

Item 6.Exhibits.

The following exhibits are filed as a part of this report:

(2)       Plan of Acquisition, reorganization, arrangement, liquidation or succession - none

(3)       Articles of Incorporation and By-laws⁽ⁱ⁾

(4)       Instruments defining rights of security holders, including indentures - none.

(10)       Material Contracts – none.

(11)       Statement regarding computation of per share earnings- none.

(15)        Letter regarding unaudited interim financial information - none.

(18)       Letter regarding change in accounting principles - none.

(19)       Reports furnished to security holders - none.

(22)       Published report regarding matters submitted to vote of security holders - none.

(23)       Consents of experts and counsel - none.

(24)       Power of Attorney - none.

(31.1)       Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. Filed herewith.

(31.2)       Certification of the Chief Accounting Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. Filed herewith.

(32.1)       Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Sect. 1350. Filed herewith.

(32.2)       Certification of the Chief Accounting Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Sect. 1350. Filed herewith.

____________________

(i) Incorporated by reference to a Registration Statement filed on Form S-18 with the Securities and Exchange Commission, 1933 Act Registration Number 2-38015C, under the Securities Act of 1933, as amended, and Incorporated by reference, with regard to Amended and Restated By-Laws, to the Company’s Current Statement on Form 8-K dated as of July 2, 2009 filed with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Biosynergy, Inc.

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Fred K. Suzuki, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Biosynergy, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Dated: March 19, 2018

EXHIBIT 31.2

CERTIFICATION OF CHIEF ACCOUNTING OFFICER

I, Laurence C. Mead, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Biosynergy, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Dated: March 19, 2018

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Report of Biosynergy, Inc. (the "Company") on Form 10-Q for the quarter ending January 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

(1)       the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended; and

(2)       the information contained in the Report fairly represents, in all material respects, the financial conditions and results of operations of the Company as of January 31, 2018, and for the period then ended.

Biosynergy, Inc.

Dated: March 19, 2018

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Report of Biosynergy, Inc. (the "Company") on Form 10-Q for the quarter ending January 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

(1)       the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended; and

(2)       the information contained in the Report fairly represents, in all material respects, the financial conditions and results of operations of the Company as of January 31, 2018, and for the period then ended.

Biosynergy, Inc.

Dated: March 19, 2018